1. Home
  2. BHAT vs APVO Comparison

BHAT vs APVO Comparison

Compare BHAT & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BHAT

Blue Hat Interactive Entertainment Technology

HOLD

Current Price

$1.39

Market Cap

59.1M

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

21.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHAT
APVO
Founded
2010
2016
Country
China
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.1M
21.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BHAT
APVO
Price
$1.39
$1.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
45.3K
1.1M
Earning Date
11-26-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,972,415.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$1.04
52 Week High
$24.50
$298.00

Technical Indicators

Market Signals
Indicator
BHAT
APVO
Relative Strength Index (RSI) 51.89 36.54
Support Level $1.24 $1.07
Resistance Level $1.45 $1.41
Average True Range (ATR) 0.10 0.09
MACD 0.03 -0.01
Stochastic Oscillator 80.00 17.14

Price Performance

Historical Comparison
BHAT
APVO

About BHAT Blue Hat Interactive Entertainment Technology

Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: